Business Context and Reporting Period
This Form 8-K filing by Atyr Pharma, Inc. (ATYR) is dated June 3, 2026. The report addresses a deficiency notice regarding the company's compliance with Nasdaq Capital Market continued listing requirements, specifically the minimum closing bid price rule.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory compliance status regarding stock price.
Material Changes
The material change reported is the extension of the compliance period for the minimum bid price requirement. Previously, the company had until June 2, 2026, to regain compliance. On June 3, 2026, Nasdaq granted an additional 180-day period, extending the deadline to November 30, 2026.
Outlook, Risks, and Management Commentary
- Compliance Status: The company failed to maintain a closing bid price of at least $1.00 per share for 10 consecutive business days prior to the initial deadline.
- Eligibility for Extension: Nasdaq determined the company meets all other initial listing standards, including the market value of publicly held shares, qualifying it for a second compliance period.
- Remediation Plan: The company intends to cure the deficiency during the second period, potentially by effecting a reverse stock split if necessary.
- Risks: If the company fails to regain compliance by November 30, 2026, its stock will be subject to delisting. There is no assurance that an appeal of a delisting determination would be successful.
- Current Listing Status: The extension letter has no immediate impact on the listing of the company's common stock on The Nasdaq Capital Market.
Investor Verification Checklist
- Verify the current closing bid price of ATYR stock relative to the $1.00 threshold.
- Monitor for any announcements regarding a reverse stock split to address the deficiency.
- Confirm the company's market value of publicly held shares remains compliant with Nasdaq standards.
- Track the timeline for the new compliance deadline of November 30, 2026.